Corcept Therapeutics (NASDAQ: CORT) Investors Who Have Suffered Losses - Contact Kaplan Fox before April 21, 2026 Lead Plaintiff Deadline

Kaplan Fox & Kilsheimer LLP has announced the filing of a class action lawsuit against Corcept Therapeutics, Inc. (NASDAQ: CORT), targeting investors who purchased the company’s stock between October 31, 2024, and December 30, 2025. The lawsuit arises from allegations that Corcept made misleading statements regarding the new drug application (NDA) for its lead product candidate, relacorilant, which is intended for treating hypercortisolism, or Cushing’s syndrome.

Throughout the class period, Corcept purportedly represented that the NDA for relacorilant had robust supporting evidence and was on the verge of FDA approval. However, the complaint claims that the defendants were aware of significant concerns from the FDA regarding the adequacy of the clinical evidence, indicating that a material risk existed that the NDA could be rejected. On December 31, 2025, this risk materialized when Corcept received a Complete Response Letter from the FDA, stating that it could not conduct a favorable benefit-risk assessment without additional evidence from the company. Following this announcement, Corcept’s stock plummeted by over 50%, which represented a loss of $35.40 per share.

Investors who have suffered losses during the specified period are encouraged to contact Kaplan Fox to discuss their eligibility to participate in the lawsuit. They can submit their information via the firm’s website or directly by email or phone. Important deadlines include a cut-off for potential lead plaintiffs, set for April 21, 2026, though investors may still be eligible for recovery without seeking lead plaintiff status. Kaplan Fox brings over 50 years of experience in securities litigation, illustrating their capability to represent affected investors effectively.

Corcept Therapeutics (NASDAQ: CORT) has recently faced significant challenges, particularly following the issuance of a Complete Response Letter from the FDA regarding its lead product candidate, relacorilant. This event has not only led to a dramatic decline in stock price—plummeting over 50%—but also exposed the company to potential legal consequences, as outlined in the recent class action lawsuit announcement by Kaplan Fox & Kilsheimer LLP. Investors impacted by losses during the class period should carefully consider their next steps.

From a market perspective, this situation signals caution for potential investors in Corcept. The company’s assurances regarding the likelihood of FDA approval and the strength of its clinical evidence now appear questionable. This skepticism could lead to prolonged market uncertainty surrounding Corcept's future prospects and impair its ability to recover significantly in the coming months.

For current shareholders, the potential for recovery in a class action lawsuit may provide a financial lifeline. Engaging with legal counsel, such as Kaplan Fox, may not only inform investors of their rights but also position them better for any potential settlements if the case proves successful.

Looking ahead, Corcept needs to focus on addressing the FDA's concerns. Securing the necessary data to support relacorilant’s effectiveness could lead to an eventual resurgence in stock value; however, this likely underscores a longer timeline for recovery. Investors should remain vigilant about ongoing developments in the company's strategic approach to regulatory challenges.

In summary, while Corcept Therapeutics presents potential long-term opportunities dependent on future approvals and market performance, current dynamics suggest that investors should tread carefully, prioritize assessing their legal options, and stay informed about new developments regarding the company’s products and regulatory status.